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Brain edema is an important pathological process during stroke. Activation of
transient receptor potential vanilloid 4 (TRPV4) causes an up-regulation of matrix
metalloproteinases (MMPs) in lung tissue. MMP can digest the endothelial basal lamina to
destroy blood brain barrier, leading to vasogenic brain edema. Herein, we tested whether
TRPV4-blockage could inhibit brain edema through inhibiting MMPs in middle cerebral
artery occlusion (MCAO) mice. We found that the brain water content and Evans blue
extravasation at 48 h post-MCAOwere reduced by a TRPV4 antagonist HC-067047. The
increased MMP-2/9 protein expression in hippocampi of MCAO mice was attenuated
by HC-067046, but only the increased MMP-9 activity was blocked by HC-067047.
The loss of zonula occludens-1 (ZO-1) and occludin protein in MCAO mice was also
attenuated by HC-067047. Moreover, MMP-2/9 protein expression increased in mice
treated with a TRPV4 agonist GSK1016790A, but only MMP-9 activity was increased
by GSK1016790A. Finally, ZO-1 and occludin protein expression was decreased by
GSK1016790A, which was reversed by an MMP-9 inhibitor. We conclude that blockage
of TRPV4 may inhibit brain edema in cerebral ischemia through inhibiting MMP-9
activation and the loss of tight junction protein.
Keywords: cerebral ischemia, transient receptor potential vanilloid 4, brain edema, matrix metalloproteinase, tight
junction protein
Introduction
Brain edema, defined as an increase of brain tissue volume resulting from an increase in its
fluid content, is an important pathological process in many central nervous system diseases,
such as cerebral ischemia, traumatic brain injury, and epilepsy. The brain edema observed
in the cerebral ischemia has a characteristic time course and it begins with a cytotoxic
phase, due to the intracellular fluid accumulation caused by energy failure after cessation
of the cerebral circulation (Gotoh et al., 1985; Song and Yu, 2014). With ongoing reperfu-
sion, the secondary vasogenic edema develops due to the disruption of blood brain barrier
(BBB) (Gotoh et al., 1985; Song and Yu, 2014). During ischemia-reperfusion, brain edema is
an important pathological process and related to unfavorable outcomes (Gotoh et al., 1985;
Song and Yu, 2014). Expression of matrix metalloproteinase (MMP) in healthy brain is rela-
tively low, but activated MMPs, especially MMP-2 and MMP-9, increase during stroke, which
leads to disruption of blood brain barrier (BBB) integrity and contributes to brain edema
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(Machado et al., 2006; Rosenberg and Yang, 2007; Lenglet et al.,
2014). Blocking MMP activation has favorable effect in prevent-
ing cerebral damage after cerebral ischemia (Cui et al., 2012; Guo
et al., 2014; Lee et al., 2014).
Transient receptor potential vanilloid 4 (TRPV4), a member
of transient receptor potential superfamily, is permeable to cal-
cium (Ca2+) (Garcia-Elias et al., 2014). TRPV4 can be activated
by diverse stimulation, including cell swelling-induced mechani-
cal stimulation, modest heat, hypotonic stimulation, endogenous
and synthetic ligands (Vincent and Duncton, 2011). Our recent
study reveals that the protein level of TRPV4 increases during
ischemia-reperfusion (Jie et al., 2014). Combined with the char-
acteristic of multipolar sensitivity, TRPV4 has been proven to be
involved in cerebral ischemic neuronal injury (Lipski et al., 2006;
Bai and Lipski, 2010; Li et al., 2013; Jie et al., 2014). BBB per-
meability is increased by activation of TRPV4 and TRPV2 com-
plex (Brown et al., 2008). In lung tissues, application of TRPV4
agonist increases the level of activated MMPs (Villalta et al.,
2014). Whether TRPV4 activation could increase MMP activity
in brain tissue remains unclear. In this study, we first exam-
ined whether blockage of TRPV4 could reduce brain edema in
a mouse model of focal cerebral ischemia by using the middle
cerebral artery occlusion (MCAO) and then explored the mecha-
nism underlying TRPV4 action by examining the effect of TRPV4
blockage/activation on the expression and activity of MMP-2/9.
Materials and Methods
Subjects
Male mice (ICR, Oirental Bio Service Inc., Nanjing, China),
weighing 25–30 g, were used. All experimental procedures were
conformed to Guidelines for Laboratory Animal Research of
Nanjing Medical University and were approved by Institutional
Animal Care and Use Committee of Nanjing Medical University.
Each experimental group contained nine mice.
Drug Treatment
Drugs were intracerebroventricularly (icv.) injected as pre-
viously reported (Jie et al., 2014). In brief, the mice were
placed in a stereotaxic device (Kopf Instruments, Tujunga, CA,
USA) after they were anesthetized. For a single icv. injection
of GSK1016790A, a 26-G stainless steel needle (Plastics One,
Roanoke, VA) was inserted into the lateral ventricle (0.3mm
posterior, 1.0mm lateral, and 2.5mm ventral to the bregma).
For repeated icv. injections of HC-067047, a 23-G stainless steel
guide cannula (Plastics One, Roanoke, VA) was first implanted
into the right lateral ventricle and anchored to the skull with
stainless steel screws and dental cement. HC-067047 was injected
beginning at 4 h after MCAO and then injected every 8 h
until 48 h post-MCAO using a 26-G stainless steel needle.
GSK1016790A at the dose of 1µM/mouse was chosen because
it causes significant hippocampal neuronal damage as well as
the changes in protein levels of phosphrylation of Akt and ERK
(Jie et al., 2014). HC-067047 at the dose of 10µM/mouse was
used because it reduces the brain infarction at 24 h post-MCAO
(Li et al., 2013). SB-3CT is the selective gelatinase inhibitor and
can inhibit MMP-9 activity in vivo (Gooyit et al., 2012). Here,
SB-3CT (25mg/kg) was intraperitoneally injected 30min before
GSK1016790A-injection and then injected once daily for 3 days.
This dose was used because it antagonized the increase of acti-
vated MMP-9 and exerted neuroprotection in transient focal
cerebral ischemia (Cui et al., 2012). Control mice were injected
with same volume of vehicle.
Preparation of Focal Cerebral Ischemia Model
Transient focal cerebral ischemia was induced by MCAO as pre-
viously described (Li et al., 2013). Sham-operated animals were
treated identically, except that the middle cerebral artery was not
occluded after neck incision.
Analysis of Tissue Water Content
The extent of post-ischemic brain edema was determined by the
wet- and dry-weight (wt) at 48 h post-MCAO. After the mice
were decapitated under anesthesia, the olfactory bulb, cerebellum
and brainstem were removed. Left (contralateral) and right (ipsi-
lateral) hemispheres were separated and then the wet weight was
determined immediately. The dry weight was determined after
drying the tissue to a constant weight at 100◦C. Tissue water
content was calculated as % H2O= (1-dry wt/wet wt)
∗100%.
Assessment of Evans Blue (EB) Extravasation
2% EB (4ml/kg) was injected via the tail vein at 46 h post-
MCAO and themice were perfused under anesthesia at 48 h post-
MCAO. The cerebral hemispheres were collected, followed by
homogenization with 50% trichloracetic acid and centrifugation.
The amount of EB in the cerebral hemispheres was quantified
at 620 nm by spectrofluorophotometry as previously described
(Wang et al., 2014). EB leakage of each sample was quantified
using a standard curve.
Western Blot Analysis
Western blot analysis was performed at 48 h post-MCAO or on
day 3 after GSK1016790A-injection as reported (Li et al., 2013;
Jie et al., 2014). Primary antibodies against MMP-2 (1:1000),
MMP-9 (1:1000) and glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) (1:5000) were obtained from Abcam and those
against ZO-1 (1:1000) and occludin (1:1000) were from Cell Sig-
naling Technology. Hippocampal samples were collected from
the hemisphere of three mice as a set of western blot analysis.
The summarized data represent the average of three experimental
sets.
Gelatin Zymography
At 48 h post-MCAO or on day 3 after GSK1016790A-injection,
the mice were perfused transcardially with ice-cold phosphate-
buffered saline under anesthesia. The hippocampi were dissected,
frozen immediately on dry ice, and stored at −80◦C. Brain
samples were homogenized in lysis buffer including protease
inhibitors on ice. After centrifugation, the supernatants were col-
lected, and total protein concentration was determined using the
Bradford assay (Bio-Rad, Hercules, CA, USA). Prepared protein
samples were loaded and separated by 10% Tris-glycine gel with
0.1% gelatin as substrate. After separation by electrophoresis, the
gel was renaturated and then incubated with developing buffer
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at 37◦C for 24 h as described previously (Lee et al., 2008). After
developing, the gel was stained with 0.5% Coomassie Blue R-250
for 30min and then destained appropriately. Proteolytic bands
in the zymography were quantified by scanning densitometry
(Quantity one, Bio-Rad).
Data Analysis
Data are expressed as means ± S.E.M and analyzed with Stata
7.0 software (STATA Corporation, USA). The EB leakage, pro-
tein levels and MMP-2/9 activity in MCAO mice or HC-067047-
treated sham-op mice or MCAO mice was normalized to those
in sham-op mice. Protein levels and MMP-2/9 activity in the
mice injected with GSK1016790A or/and SB-3CT was normal-
ized to those in the vehicle-injected mice (control mice). ANOVA
followed by Bonferroni’s post-hoc test was used for statistical anal-
ysis, and significance levels were set at P < 0.05 and P <
0.01.
Results
Effect of TRPV4 Antagonist on the Brain Water
Content and EB Extravasation in MCAO Mice
Brain edema began to develop as early as 3 h after MCAO and
progressed rapidly to a maximum on the second and third day,
and gradually regressed thereafter (Gotoh et al., 1985). Therefore,
we examined the effect of HC-067047, a specific TRPV4 antago-
nist, on the brain water content at 48 h post-MCAO. As shown
in Figure 1A, the brain water content of ischemic ipsilateral
hemisphere was 86.03 ± 1.55% in MCAO mice. After treatment
with HC-067047, the water content of ipsilateral hemisphere was
reduced to 81.36 ± 1.23% (P < 0.01). EB extravasation in the
ipsilateral hemisphere was increased at 48 h post-MCAO. A sig-
nificant decrease of EB extravasation in the ipsilateral hemisphere
was found when the MCAO mice were treated with HC-067047
(P < 0.01). Application of HC-067047 had no effect on the water
content or EB leakage in the contralateral hemisphere (P > 0.05,
FIGURE 1 | Effect of TRPV4 antagonist on brain water content, EB
extravasation, the protein levels and activity of MMP-2/9, and the
protein levels of ZO-1 and occludin at 48h post-MCAO. (A) Bar
graphs show the brain water content and EB extravasation in the
ipsilateral hemisphere in sham-op, MCAO, and HC-067047-treated
MCAO mice. (B) The protein levels of MMP-2 and MMP-9 increased at
48 h post-MCAO, which was sensitive to HC-067047 treatment. By
contrast, only the increased activity of MMP-9 was markedly blocked by
HC-067047 treatment. (C,D) The protein levels of ZO-1 (C) and
occludin (D) decreased at 48 h post-MCAO, which was markedly
reversed by HC-067047 treatment. **P < 0.01 vs. sham-op, #P < 0.05
and ##P < 0.01 vs. MCAO mice.
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data not shown). The above results indicate that blockage of
TRPV4 inhibits the formation of brain edema following ischemic
insult.
Effect of TRPV4 Antagonist on the Protein
Expression and Activity of MMP-2/9 and the
Protein Expression of ZO-1 and Occludin in
MCAO Mice
During stroke, MMP-2 and MMP-9 are up-regulated, leading to
increased BBB permeability through degradation of endothelial
matrix proteins. Figure 1B shows that protein levels of MMP-2
and MMP-9 markedly increased at 48 h post-MCAO, and this
increase was attenuated by HC-067047 (P < 0.05 for MMP-
2, P < 0.01 for MMP-9). Moreover, an increase of MMP-2
and MMP-9 activity was found at 48 h post-MCAO, but only
the increase of MMP-9 activity was markedly inhibited by HC-
067047 treatment (P < 0.01). We then studied the effect of
TRPV4-blockage on the expression of zonula occludens-1 (ZO-1)
and occludin, two major proteins involved in the tight junc-
tions of BBB. Figures 1C,D show that protein levels of ZO-1 and
occludin decreased markedly at 48 h post-MCAO, which was res-
cued by the treatment with HC-067047 (P < 0.05 for ZO-1,
P < 0.01 for occludin). These results indicate that blockage of
TRPV4 could inhibit the activated MMP-9 level and rescue the
loss of ZO-1 and occludin in MCAOmice, which may benefit for
the integrity of BBB.
Effect of TRPV4 Agonist on the Protein
Expression and Activity of MMP-2/9 and the
Protein Expression of ZO-1 and Occludin
As shown in Figure 2A, the protein levels of MMP-2 andMMP-9
were higher in the mice injected with GSK1016790A (a TRPV4
agonist), when compared to control values (P < 0.05 for MMP-
2, P < 0.01 for MMP-9). It was noted that only the activity
of MMP-9 was increased markedly by GSK1016790A treatment
(P < 0.01). Protein levels of ZO-1 and occludin were significantly
lower in GSK1016790A-injectedmice, compared to control levels
(P < 0.01 in each case) (Figures 2B,C). It was noted that higher
protein levels of ZO-1 and occludin were found in the mice co-
injected with GSK1016790A and SB-3CT (an MMP-9 inhibitor)
(P < 0.05 for ZO-1, P < 0.01 for occludin). These results
indicate that activation of TRPV4 may facilitate the activation of
MMP-9 to decrease the protein of ZO-1 and occludin.
Discussion
During the cerebral ischemica, cytotoxic cell swelling develops
shortly after the occlusion of cerebral artery and is caused by
energy failure. It is the earliest morphological change that cannot
be avoided, but this cellular morphology change indeed facili-
tates the activation of TRPV4. Vasogenic edema is a secondary
phase of brain edema, resulting from BBB breakdown (Gotoh
et al., 1985; Song and Yu, 2014). Here, application of HC-067047
decreased the water content and EB leakage in the ipsilateral
hemisphere of MCAO mice (Figure 1A) and this effect of clos-
ing TRPV4 is more likely due to the inhibition of vasogenic
edema.
MMP is a family of zinc-dependent endopeptidases. Among
them, MMP-2 and MMP-9 are major MMPs that are involved in
BBB injury and neuronal death after cerebral ischemia (Machado
et al., 2006; Rosenberg and Yang, 2007; Lenglet et al., 2014).
In vitro and in vivo studies have proven that blocking MMP
activation is a potential therapeutic strategy for preventing neu-
ronal death through preserving BBB integrity following ischemic
brain injury (Machado et al., 2006; Fu et al., 2014). Here, the
FIGURE 2 | Effect of TRPV4 agonist on the protein levels and activity
of MMP-2/9 and the protein levels of ZO-1 and occluding. (A) The
protein levels of MMP-2/9 increased significantly after icv. injection of
GSK1016790A, but only the activity of MMP-9 increased markedly after
GSK1016790A treatment. (B,C) Lower protein levels of ZO-1 (B) and
occludin (C) were found in GSK1016790A-injected mice, which was
sensitive to a MMP-2/9 inhibitor. *P < 0.05 and **P < 0.01 vs. control,
#P < 0.05 and ##P < 0.01 vs. GSK1016790A-injected mice.
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increase of MMP-9 protein expression and activity at 48 h post-
MCAO was markedly blocked by TRPV4 antagonist. Consis-
tently, MMP-9 protein level and activity in hippocampus were
higher in GSK1016790A-injected mice. Although the protein
level of MMP-2 was increased by application of TRPV4 ago-
nist, the activity was nearly unaffected (Figures 1B, 2A). Here,
we also found that GSK1016790A-induced modulation of MMP-
9 protein expression and activity was blocked by application
of TRPV4 antagonist HC-067047 (Supplementary Figure 1).
Therefore, MMP-9 is more likely the target of TRPV4. Recent
studies show that the treatment with TRPV4 agonist leads to
an increase of activated MMPs (MMP-1, MMP-2 and MMP-9)
in lung tissues, which is dependent on TRPV4-mediated Ca2+
influx (Li et al., 2011; Villalta et al., 2014). The pathological
changes in a stroke may facilitate the activation of TRPV4 and
moreover, an increased TRPV4 protein level is found during
ischemia-reperfusion (Jie et al., 2014). Besides the Ca2+ entry
mediated by TRPV4, activation of TRPV4 enhances NMDA-
activated current (Li et al., 2013). Therefore, it is proposed that
during stroke, the over- or hyper-activation of TRPV4 aggra-
vates the increase of [Ca2+]i, helping to increase the activated
MMP-9.
The BBB is formed by brain endothelia cells lining the
microvascular system that is sealed by tight junction (TJ).
TJ is crucial for the permeable property of BBB. ZO-1 and
occludin are two major proteins involved in TJ of BBB (Salama
et al., 2006). ZO-1 is a peripheral membrane protein and con-
sidered an indicator for the presence of TJ. Occludin inter-
acts with ZO-1, which in turn, links TJ to the cytoskeleton.
Here, a decrease of ZO-1 and occludin protein was found
in GSK1016790A-injected mice (Figures 2B,C) and the loss of
ZO-1 and occludin protein at 48 h post-MCAO was markedly
blocked by HC-067047 (Figures 1C,D). Activation of MMP
opens the BBB by degrading TJ and increases BBB permeabil-
ity after stroke, and an MMP inhibitor prevents the degrada-
tion of TJ and attenuates BBB disruption (Cui et al., 2012). The
present study found that GSK1016790A-induced decrease of ZO-
1 and occludin protein was significantly reserved by an MMP-9
inhibitor (Figures 2B,C). Moreover, GSK1016790A-induced the
loss of ZO-1 and occludin was completely blocked by HC-067047
(Supplementary Figure 1). Our data suggested that during cere-
bral ischemia, activation of TRPV4 may increase the activated
MMP-9 level, leading to the loss of ZO-1 and occludin. In the
future study, TRPV4 knockout mice will be needed to further
clarify TRPV4-induced the above action and its involvement in
the brain edema formation during cerebral ischemia.
Conclusion
Brain edema, either a cause or a consequence, disturbs physio-
logical neuronal function and amplifies tissue damage. Together
with our early reports (Li et al., 2013; Jie et al., 2014), the present
data indicate that during cerebral ischemia, blockage of TRPV4
may inhibit the activation of MMP-9 and the loss of ZO-1 and
occludin, which helps to reduce the disruption of BBB integrity
and the subsequent vasogenic brain edema and brain injury.
Our unpublished data find that application of TRPV4 agonist
decreases the protein of claudin-5 in hippocampus, indicating
that, besides ZO-1 and occludin, activation of TRPV4 may result
in the loss of other TJ protein. As is known that aquaporin-4
(AQ4) plays an important role in the formation of brain edema
during stroke. TRPV4 and AQ4 co-expressed in the astrocytic
endfeet and it acts as an important structural and functional part-
ner of AQ4 (Benfenati et al., 2011). Therefore, TRPV4 is likely a
potential target for treating brain edema during cerebral ischemia
and other pathological process.
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